Ivastar 5mg Tablet contains Ivabradine 5mg as its active ingredient, primarily indicated for the treatment of chronic stable angina pectoris and chronic heart failure. Ivabradine acts selectively on the sinoatrial node by inhibiting the If current, resulting in heart rate reduction without affecting myocardial contractility or intracardiac conduction. This mechanism helps to decrease myocardial oxygen demand, thereby alleviating angina symptoms and improving exercise tolerance in patients with coronary artery disease. In chronic heart failure, Ivabradine is used to reduce hospitalization risk by controlling elevated heart rates in patients with systolic dysfunction who remain symptomatic despite optimal standard therapy, including beta-blockers. Ivastar is typically administered orally, with dosage tailored according to patient response and heart rate monitoring. It is contraindicated in patients with acute decompensated heart failure, bradycardia, sick sinus syndrome, or severe hepatic impairment. Common adverse effects include bradycardia, luminous phenomena (phosphenes), and dizziness. Ivabradine should be used cautiously in patients with atrial fibrillation or conduction disturbances. Regular monitoring of heart rate and rhythm is recommended during treatment. Ivastar 5mg Tablet offers a targeted approach to heart rate control, improving clinical outcomes in selected cardiovascular conditions.